Charles Schwab’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-994,037
| Closed | -$39.1M | – | 3703 |
|
|
2023
Q2 | $39.1M | Buy |
994,037
+16,583
| +2% | +$585K | 0.01% | 1029 |
|
|
2023
Q1 | $23.8M | Buy |
977,454
+13,093
| +1% | +$287K | 0.01% | 1330 |
|
|
2022
Q4 | $20.6M | Buy |
964,361
+140,208
| +17% | +$2.99M | 0.01% | 1417 |
|
|
2022
Q3 | $14.8M | Buy |
824,153
+522,265
| +173% | +$6.86M | 0.01% | 1597 |
|
|
2022
Q2 | $2.9M | Buy |
301,888
+672
| +0.2% | +$8.44K | ﹤0.01% | 2431 |
|
|
2022
Q1 | $5.07M | Buy |
301,216
+6,286
| +2% | +$92.9K | ﹤0.01% | 2274 |
|
|
2021
Q4 | $4.93M | Buy |
294,930
+31,193
| +12% | +$511K | ﹤0.01% | 2362 |
|
|
2021
Q3 | $4.28M | Buy |
263,737
+37,326
| +16% | +$406K | ﹤0.01% | 2450 |
|
|
2021
Q2 | $1.43M | Buy |
226,411
+20,105
| +10% | +$130K | ﹤0.01% | 2815 |
|
|
2021
Q1 | $1.28M | Buy |
206,306
+5,137
| +3% | +$31.2K | ﹤0.01% | 2776 |
|
|
2020
Q4 | $1.39M | Sell |
201,169
-64
| -0% | -$410 | ﹤0.01% | 2685 |
|
|
2020
Q3 | $1.14M | Buy |
201,233
+94,625
| +89% | +$451K | ﹤0.01% | 2644 |
|
|
2020
Q2 | $544K | Buy |
+106,608
| New | +$444K | ﹤0.01% | 2797 |
|
|
2019
Q3 | – | Sell |
-29,361
| Closed | -$39K | – | 3197 |
|
|
2019
Q2 | $39K | Hold |
29,361
| – | – | ﹤0.01% | 3165 |
|
|
2019
Q1 | $42K | Buy |
+29,361
| New | +$41.1K | ﹤0.01% | 3165 |
|
|
2017
Q3 | – | Sell |
-71,721
| Closed | -$184K | – | 3098 |
|
|
2017
Q2 | $184K | Sell |
71,721
-46,445
| -39% | -$127K | ﹤0.01% | 3044 |
|
|
2017
Q1 | $433K | Buy |
118,166
+49,928
| +73% | +$211K | ﹤0.01% | 2694 |
|
|
2016
Q4 | $330K | Sell |
68,238
-39,423
| -37% | -$1.17M | ﹤0.01% | 2812 |
|
|
2016
Q3 | $4.97M | Buy |
107,661
+4,652
| +5% | +$262K | 0.01% | 1660 |
|
|
2016
Q2 | $5.26M | Buy |
103,009
+13,398
| +15% | +$666K | 0.01% | 1528 |
|
|
2016
Q1 | $3.79M | Buy |
89,611
+1,535
| +2% | +$78.2K | 0.01% | 1689 |
|
|
2015
Q4 | $6.92M | Buy |
88,076
+6,482
| +8% | +$375K | 0.01% | 1298 |
|
|
2015
Q3 | $3.31M | Buy |
81,594
+29,301
| +56% | +$1.55M | ﹤0.01% | 1752 |
|
|
2015
Q2 | $2.72M | Buy |
52,293
+10,532
| +25% | +$524K | ﹤0.01% | 1920 |
|
|
2015
Q1 | $1.94M | Buy |
41,761
+11,476
| +38% | +$596K | ﹤0.01% | 2068 |
|
|
2014
Q4 | $1.36M | Buy |
30,285
+671
| +2% | +$28.2K | ﹤0.01% | 2213 |
|
|
2014
Q3 | $1.15M | Buy |
29,614
+561
| +2% | +$22K | ﹤0.01% | 2234 |
|
|
2014
Q2 | $1.23M | Buy |
29,053
+7,324
| +34% | +$269K | ﹤0.01% | 2234 |
|
|
2014
Q1 | $777K | Buy |
21,729
+3,236
| +17% | +$109K | ﹤0.01% | 2404 |
|
|
2013
Q4 | $599K | Buy |
+18,493
| New | +$549K | ﹤0.01% | 2517 |
|
Charles Schwab's ISEE Position: Q3 2023 in Review
Charles Schwab sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 994,037 shares — an estimated $39.1M sold.
Charles Schwab first reported a position in ISEE in Q4 2013 and held it in 30 quarters. The position peaked at $39.1M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Charles Schwab reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Charles Schwab sold 994,037 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $39.1M.
- Charles Schwab first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 30 quarters.
- Charles Schwab's IVERIC bio, Inc. Common Stock position peaked at $39.1M in Q2 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.